GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MiniMed Group, Inc. Common Stock MMED · USD

US listing · 🇺🇸 United States

Compare

17.88

+7.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$3.10bn

FY2023FY2026

Net income

−$331.0m

FY2023FY2026

Free cash flow

−$420.0m

FY2023FY2026

Shareholders' equity

$3.61bn

FY2023FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023
Revenue$3.10bn$2.71bn$2.47bn$2.25bn
Gross profit$1.68bn$1.52bn$1.44bn$1.31bn
Research and development$448.0m$438.0m$437.0m$429.0m
Operating income$49.0m−$202.0m−$69.0m−$69.0m
Net income−$331.0m−$250.0m−$112.0m−$96.0m
Diluted earnings per share-1.18-0.89-0.40-0.34

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023
Total assets$4.63bn$4.20bn$4.09bn—
Cash and short-term investments$298.0m$11.0m$54.0m—
Total liabilities$1.02bn$870.0m$646.0m—
Debt$145.0m$11.0m$8.0m—
Shareholders' equity$3.61bn$3.33bn$3.45bn—
Shares outstanding281m281m281m281m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023
Cash from operations−$197.0m$140.0m$41.0m−$6.0m
Capital spending−$223.0m−$193.0m−$148.0m−$167.0m
Free cash flow−$420.0m−$53.0m−$107.0m−$173.0m

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025
Revenue$843.0m$837.0m$790.0m$752.0m$723.0m$724.0m$687.0m
Gross profit$465.0m$480.0m$362.0m$428.0m$409.0m$402.0m$395.0m
Operating income$38.0m$82.0m−$93.0m−$10.0m$3.0m−$204.0m$22.0m
Net income—−$183.0m−$119.0m−$27.0m−$19.0m−$209.0m−$10.0m
Diluted earnings per share—-0.65-0.42-0.10-0.07-0.74-0.04
Cash from operations−$49.0m−$170.0m$66.0m$48.0m−$141.0m$83.0m$24.0m
Capital spending−$41.0m−$56.0m−$53.0m−$61.0m−$53.0m−$57.0m−$50.0m
Free cash flow−$90.0m−$226.0m$13.0m−$13.0m−$194.0m$26.0m−$26.0m
Total assets$4.72bn$4.63bn$4.34bn$4.24bn—$4.20bn—
Cash and short-term investments$207.0m$298.0m$10.0m$350.0m—$11.0m—
Debt$9.0m$145.0m$11.0m——$11.0m—
Shareholders' equity$3.62bn$3.61bn$3.46bn$3.74bn—$3.33bn—

Financial ratios

Data as of 19 Oct 2026

FY2026FY2025FY2024FY2023
Gross margin54.2%56.2%58.2%58.3%
Operating margin1.6%-1.3%-2.8%-3.4%
Net margin-10.7%-9.2%-4.5%-4.3%
Return on equity-9.2%-7.5%-3.2%—
Return on assets-7.1%-6.0%-2.7%—
Free cash flow yield0.5%6.8%——
Revenue growth14.3%10.0%10.0%—
Earnings growth32.4%123.2%16.7%—
Current ratio1.92x1.32x1.73x—
Debt to equity0.04x0.00x0.00x—
Equity ratio78.0%79.3%84.2%—
R&D as a share of sales14.4%16.1%17.7%19.1%
Buybacks as a share of market value-0.1%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.4%——
Net income51.1%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin55.1%56.5%——

Valuation history

At each fiscal year end

FY2026
Price to earnings-16.4
Price to sales1.8

Market value over time

31 Mar 2026 to 16 Oct 2026, in USD

$4.19bn$4.91bn

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.